Artesunate and Pyronaridine — Competitive Intelligence Brief

Artesunate and Pyronaridine (Artesunate and Pyronaridine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial combination. Area: Infectious Disease.

marketed Antimalarial combination Malaria parasite (Plasmodium species) — multiple targets including heme polymerization and oxidative stress pathways Infectious Disease Small molecule

Target snapshot

Artesunate and Pyronaridine (Artesunate and Pyronaridine) — Armed Forces Research Institute of Medical Sciences, Thailand. Artesunate and pyronaridine are antimalarial agents that work synergistically to kill malaria parasites by generating reactive oxygen species and disrupting parasite metabolism.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Artesunate and Pyronaridine TARGET	Artesunate and Pyronaridine	Armed Forces Research Institute of Medical Sciences, Thailand	marketed	Antimalarial combination	Malaria parasite (Plasmodium species) — multiple targets including heme polymerization and oxidative stress pathways
lumefantrine-artemether	lumefantrine-artemether	Centers for Disease Control and Prevention	marketed	Antimalarial combination	Malaria parasite (Plasmodium) hemoglobin metabolism and mitochondrial function
Mefloquine- Artesunate	Mefloquine- Artesunate	Centers for Disease Control and Prevention	marketed	Antimalarial combination	Parasite heme detoxification pathway; artemisinin-iron adducts generating reactive oxygen species
Artesunate + Sulfadoxine-Pyrimethamine	Artesunate + Sulfadoxine-Pyrimethamine	Sanofi	marketed	Antimalarial combination	Plasmodium falciparum (multiple targets: artemisinin-induced oxidative stress; dihydrofolate reductase; dihydropteroate synthase)
artemether-lumefantrine (ALN)	artemether-lumefantrine (ALN)	Jhpiego	marketed	Antimalarial combination	Plasmodium falciparum heme metabolism and parasite membranes
Atovaquone / Proguanil	Atovaquone / Proguanil	Radboud University Medical Center	marketed	Antimalarial combination	Mitochondrial electron transport chain (atovaquone); dihydrofolate reductase (proguanil)
Artesunate plus Amodiaquine	Artesunate plus Amodiaquine	Bernhard Nocht Institute for Tropical Medicine	marketed	Antimalarial combination therapy	Plasmodium falciparum (multiple parasite targets including heme detoxification pathway and DNA synthesis)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial combination class)

1. Centers for Disease Control and Prevention · 4 drugs in this class
2. Armed Forces Research Institute of Medical Sciences, Thailand · 4 drugs in this class
3. London School of Hygiene and Tropical Medicine · 3 drugs in this class
4. Sanofi · 2 drugs in this class
5. Menzies School of Health Research · 2 drugs in this class
6. Fundação de Medicina Tropical Dr. Heitor Vieira Dourado · 1 drug in this class
7. Epicentre · 1 drug in this class
8. Jhpiego · 1 drug in this class
9. Charite University, Berlin, Germany · 1 drug in this class
10. Ifakara Health Institute · 1 drug in this class